empty
 
 
ro
Search
Support
Instant account opening
Trading Platform
Deposit/Withdraw
Search
Pentru Începători Pentru Traderi Pentru Parteneri Luați o pauză Despre InstaSpot
ro
Pentru Traderi
Grafice
#ALNY

#ALNY (Alnylam Pharmaceuticals Inc.). Cursul de schimb și diagramele online.

#ACB Reveniți la lista instrumentelor #AMGN

Convertor valutar

Alnylam Pharmaceuticals Inc.
240.1 USD
09 Jan 2025 18:12
Modificarea pretului (% chg)
$0
(0%)
Inchidere
Inchidere

Pretul de inchidere, ziua precedenta.
$240.1
Deschiderea
Deschiderea

Pretul de deschidere.
$234.37
Petul maxim
Petul maxim

Pretul maxim al ultimei zile de tranzactionare.
$240.1
Pretul minim
Pretul minim

Pretul minim al ultimei zile de tranzactionare.
$240.1
52-sapt. max.
52-sapt. max.

Pretul maxim din ultimele 52 spatamani.
$240.1
52-sapt. min.
52-sapt. min.

Pretul minim din ultimele 52 saptamani.
$234
Descărcați arhiva
Cumpărați
240.1
Vindeți
240.1
Deschideți graficul în ecran complet
Cumpărați
240.1
Vindeți
240.1
Descărcați arhiva
Deschideți graficul în ecran complet

Alnylam Pharmaceuticals Inc. About company

Alnylam Pharmaceuticals Inc. is an American biopharmaceutical company, founded in 2002. The firm is mainly involved in the research and development of drugs for treating genetic disorders.

In 2016, Alnylam Pharmaceuticals Inc. was added to the Forbes list of the world’s 100 most innovative growth companies.

This year, the market capitalization of Alnylam Pharmaceuticals Inc. totals $17.65 billion. In 2021, it raised revenue of $844.29 million. In the first six months of 2022, the company earned as much as $224.82 million.

Alnylam Pharmaceuticals Inc.’s shares and factors shaping their value

The company has been listed on the NASDAQ exchange since 2004 under the ALNY ticker. Its share value currently totals $200-205. Over the past 12 months, ALNY has fluctuated in the range of $117 to $236.

When trading the firm’s stock, you should pay attention to the following factors:

  • The company has a heavy dependence on the state of the healthcare sector as a whole. Thus, new COVID outbreaks have a negative influence on its revenue growth;
  • The company occasionally introduces new drugs to the market, conducting clinical and laboratory trials and publishing the results beforehand;
  • Constantly growing revenues are the firm’s advantage;
  • Enough own funds to finance projects without the need to additionally issue securities.

Nu puteti sa vorbiti acum?
Puneti intrebare in chat.